NEWS AND MEDIA
Our Commitment to Safety as we Navigate Coronavirus
Mar 24, 2020
We have always been guided by our core values—Collaboration, Integrity, Courage, and Innovation—but now, facing the challenges posed by COVID-19, our core values have taken on new meaning. The health and safety of our colleagues, customers and community, along with the continuity of business operations – critical to serve patients who rely on our medicines and products – are our top priorities.
Our manufacturing facilities are open and operating but, where our workforce can work from home, they are doing so. We have taken special measures to protect those who continue to work on-site during this time, including enhanced cleaning, shift adjustments, social distancing, and business continuity planning, among other measures.
Our business remains open. Our products are available, and we have not identified any supply chain risks at this time. We continue to progress our public health initiatives and our pipeline. Please continue to contact us through your normal channels. Our medical team is available and if you have questions related to our products please contact us; 1-888-726-7535; www.AskPurdueMedical.com. Other contact information can be found here.
We are particularly concerned that the pandemic is triggering indirect health risks for people with (or those at risk of experiencing) substance use disorders. Through our office of Corporate Social Responsibility, Purdue is providing $500,000 in additional monetary support to local and national organizations focused on the pandemic, as well as those delivering harm reduction programs, improving access to medication-assisted treatment, and supporting continuity of recovery services during the pandemic.
We are confident that, by facing new challenges through a data-driven, health-conscious, and business continuity-focused lens, we can continue to serve those who rely on our medicines and products.
Recent News
Purdue Pharma Announces Landmark Agreement with Oklahoma to Advance the Treatment of Addiction
Settlement will establish national center for addiction studies and treatment in Tulsa; Sackler family announces voluntary contribution to support national center STAMFORD, Conn., March 26, 2019 — Purdue Pharma L.P. today announced that it has entered into a landmark…
FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the Emergency Treatment of Known or Suspected Opioid Overdose
Committed to advancing solutions to the opioid public health crisis, Purdue will not profit from nalmefene HCl STAMFORD, Conn., March 13, 2019 — Purdue Pharma L.P. today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to…
Purdue Pharma Statement to 60 Minutes Regarding the Segment on Opioid Medicines Expected to Air Sunday, February 24, 2019
In 1995, the U.S. Food and Drug Administration (FDA) approved OxyContin® (oxycodone HCI) extended-release tablets CII (current Full Prescribing Information and Box Warning here)1 based on a robust set of clinical trials, which the FDA dubbed at the time the “gold…
Patients Who Receive Information About the Importance of Safe Disposal Are Three Times More Likely to Dispose of Unused Prescription Opioid Medications
Survey study sponsored by Purdue Pharma and published in the Journal of Pain Research examines factors that contribute to the safe disposal of opioids STAMFORD, Conn., February 20, 2019 — Purdue Pharma L.P. today announced the publication of a survey study that found…
Purdue Pharma L.P. and Alivio Therapeutics Enter into Partnership to Advance ALV-107, a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment
Alivio to receive up to $14.75 million in upfront and near-term license exercise payments and is eligible to receive royalties on product sales and over $260 million in research and development milestones STAMFORD, Conn. and BOSTON – Jan 28, 2019 — Purdue Pharma L.P.…
Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain
Partners to research novel targets for reductions in pain STAMFORD, Conn., and BEDFORD, Mass., January 7, 2019 – Purdue Pharma L.P. and Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization…
Purdue Pharma L.P. Enters into Exclusive Option Agreement to Acquire SpineThera, Inc. and Its Non-Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain
Purdue will support SpineThera’s clinical development program to evaluate sustained-release, injectable treatment options for pain in and near the spine Purdue Pharma L.P. and SpineThera, Inc. today announced that the companies have entered into an agreement that…
Purdue Pharma Urges Accuracy in Communications on Abuse-Deterrent Formulations of Opioids
STAMFORD, Conn. – September 24, 2018 – Marcelo E. Bigal MD, Ph.D. Chief Medical Officer, Purdue Pharma L.P., issued the following statement today: The nation’s opioid crisis is a significant and urgent public health challenge, and Purdue Pharma is deeply concerned…
Purdue Pharma L.P. and Geisinger Present Interim Analysis from Wearable Health Technology Clinical Trial at PAINWeek® 2018 Annual Conference
Purdue Pharma L.P. and Geisinger Present Interim Analysis fromWearable Health Technology Clinical Trial at PAINWeek® 2018 Annual ConferenceResults Show Successful Uptake of Technology and Increased Patient-Provider Communication STAMFORD, Conn., and DANVILLE, Pa. –…
Purdue Pharma L.P. to Present Data from Three Research Studies at PAINWeek® 2018 Annual Conference
Purdue Pharma L.P. to Present Data from Three Research Studies atPAINWeek® 2018 Annual ConferenceStudies Underscore Company’s Ongoing Commitment to Working Collaboratively onMeaningful Solutions to Address the Opioid Crisis STAMFORD, Conn., September 6, 2018 – Purdue…